A War on High Drug Prices Could Boost Biosimilars

Complex biologic medications that are made in living cells are some of the most expensive drugs on the market, but expiring patents on biologics are putting $100 billion in sales up for grabs by 2020, according to GBI Research. Stealing market share away from costly biologics as they lose patent protection got companies, including Pfizer (NYSE: PFE), Amgen (NASDAQ: AMGN) and Mylan (NASDAQ: MYL) betting big bucks on biosimilars that work similarly, and a new Trump administration proposal this past week could boost biosimilar sales significantly in the future.